Report from the 39th Annual Meeting of the European Association for the Study of the Liver, 14–18 April 2004, Berlin, Germany.
References
1.
ZeuzemS., HultcrantzR., BourliereM., GoeserT., MarcellinP., Sanchez-TapiasJ., SarrazinC., HarveyJ., BrassC., & AlbrechtJ.Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.Journal of Hepatology2004; 40: 993–999.
2.
MannsM.P., McHutchisonJ.G., GordonS.C., RustgiV.K., ShiffmanM., ReindollarR., GoodmanZ.D., KouryK., LingM., & AlbrechtJ.K.Peginterferon alfa-2b compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
3.
MangiaA., MinervaN., RicciG.L., RomanoM., CarrettaV., PersicoM., BaccaD., SpiritoF., VinelliF., AnneseM., GiangasperoA., ScottoG., & AndriulliA.HCV genotype 2 and 3 can be cured by PEG-IFN-alfa2b and RBV for 12 wks: a randomised controlled study.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 93.
4.
ButiM., ValdesA., MendezC., SchaperM., SauledaS., Rodriguez-FriasF., JardiR., EstebanR., & GuardiaJ.HCV core Ag as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alfa-2b plus ribavirin.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 466.
5.
GonzalezV., PlanasR., PadillaE., PerezC., GimenezD., MatasL., MorillasR.M., CabreE., SolaR., & DiagoM.Total HCV core antigen correlates with HCV RNA, and predicts sustained virological response (SVR) to peginterferon alfa 2-a (peg-IFN) and ribavirin (rib) therapy in chronic hepatitis C (CHC).39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 480.
6.
LunelF., PivertA., PayanC. & the members of the RIBAVIC scientific committee. Comparison of HCV RNA and HCV core antigen kinetics in the follow up of a therapeutic protocol in HCV-HIV co-infected patients (RIBAVIC).39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 491.
7.
BrauN., Rodriguez-TorresM., SalvatoreM., Ríos-BedoyaC., FernandezA., ParonettoP., & Rodriguez-OrengoJ.Control of HIV viral load through highly active antiretroviral therapy (HAART) slows down liver fibrosis progression in HIV/HCV-coinfection and makes it the same as in HCV-monoinfection. The Puerto Rico-New York Hepatitis C study group.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 91.
8.
LuiseS., BernardinelloE., CavallettoL., ChemelloL., De CarloS., MattielloK., GottardoA., MezzocolliI., & GattaA.Kinetic of virological response during peg-IFNs in chronic hepatitis C.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 490.
9.
TorrianiF.J., RockstrohJ., Rodriguez-Torres, LissenE., GonzalesJ., LazzarinA., CarosiG., SasadeuszJ., KatlamaC., & DieterichD.Final week-72 results of the AIDS PEGASYS ribavirin international co-infection trial (APRICOT): a randomized, partially blinded, multinational comparative trial of peginterferon alfa-2a (40kd) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) vs interferon alfa-2a (IFN.) 39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 92.
10.
CasteraL., ConstantA., HenryC., ChampenoitP., SauvéG., de LédinghenV., BernardP.H., FoucherJ., Demotes-MainardJ., & CouzigouP.Psychiatric events during peginterferon and ribavirin therapy in chronic hepatitis C (CHC): results of a prospective study in 98 patients.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 470.
11.
MarkowitzJ.S., GuttermanE.M., & KlaskalaW.Prophylactic prescribing of antidepressants to patients treated for hepatitis C in a US healthcare plan.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 493.
12.
ReddyK.R., FriedM.W., ShiffmanM.L., HadziyannisS.J., SetteH., MorganT.R., SchaeferS., & PopescuM.The influence of cumulative exposure to combination peginterferon alfa-2a (40 kd) (PEGASYS) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 505.
13.
GishR., AroraS., NelsonD., FernandezH., & LamonK.Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naive patients.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 479.
14.
MangiaA., LeandroG., HelblingB., RennerE.L., TaboneM., SidoliL., CaroniaS., FosterG.R., ZeuzemS., BergT., Di MarcoV., CinoN., & AndriulliA.Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta analysis of individual patient data from six clinical trials.Journal of Hepatology2004; 40: 478–483.
15.
FargionS., BorzioM., MaraschiA., CargnelA. & Gel Gruppo Epatologico Lombardo. Sustained virological response (SVR) to peginterferon alfa-2a (40kd) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC).39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 475.
16.
MarcellinP., HorsmansY., NevensF., GrangeJ.D., BronowickiJ.P., VetterD., KauffmanR., KnoxS., McNairL., MoseleyS., & AlamJ.A Phase II, placebo-controlled study of merimepodib (VX-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 492.
17.
SchiffE.R., PockrosP., SchiffmanM.L., McHutchisonJ., GishR., AfdhalN.H., MakhviladzeM., OltersdorfT., & ShapiroD.A.Oral IDN-6556, an anti-apoptotic caspase inhibitor, lowers aminotransferases in HCV patients.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 66.
18.
HerrmannE., ZeuzemS., SarrazinC., HinrichsenH., BenhamouY., WedemeyerH., SteinmannG., & NehmizG.Hepatitis C viral kinetics in chronically infected patients treated with the serine protease inhibitor BILN 2061.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 67.
19.
LinC., LinK., LuongY.P., RaoB.G., WeiY.Y., BrennanD., FulghumJ., FrantzD., HsaioH.M., MaS., MaxwellJ., PerniR.B., GatesC.A., & KwongA.D.VX-950, a novel HCV protease inhibitor, retains potency against BILN-2065 resistant replicon cells: computational analysis indicates that resistance develops via different mechanisms.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 59.
20.
GodofskyE., AfdhalN., RustgiV., ShickL., DuncanL., ZhouX.J., ChaoG., FangC., FielmanB., MyersM., & BrownN.A.First clinical results for a novel antiviral treatment for hepatitis C: a phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 96.
21.
KorfM., JarczakD., MannsM.P., & KrugerM.Small interfering RNAs targeting highly conserved regions inhibit hepatitis C virus translation and replication.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 400.
22.
ArribillagaL., SarobeP., GorraizM., Bruna-RomeroO., Borras-CuestaF., PrietoJ., RuizJ., & LasarteJ.J.Protection against infection with an HCV-recombinant vaccinia virus by vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS4a protein.39th Annual Meeting of the European Association for the Study of the Liver. 14–18 April 2004, Berlin, Germany. Abstract 387.
